Download PDF
Nuklearmedizin 1976; 15(06): 297-299
DOI: 10.1055/s-0038-1624981
Originalarbeiten — Original Articles
Schattauer GmbH

Adrenal Scintigraphy with 131I-Adosterol

A. Kasperlik-Zaluska
1   From the Endocrinology Clinic (Head: Prof. Dr. W. Hartwig) Centre for Postgraduate Medical Education and the Nuclear Medicine Department, Institute of Oncology (Head: Doc. Dr. J. Szymendera) Warsaw
,
O. A. Chomicki
1   From the Endocrinology Clinic (Head: Prof. Dr. W. Hartwig) Centre for Postgraduate Medical Education and the Nuclear Medicine Department, Institute of Oncology (Head: Doc. Dr. J. Szymendera) Warsaw
,
W. Hartwig
1   From the Endocrinology Clinic (Head: Prof. Dr. W. Hartwig) Centre for Postgraduate Medical Education and the Nuclear Medicine Department, Institute of Oncology (Head: Doc. Dr. J. Szymendera) Warsaw
,
A. Mikołajków
1   From the Endocrinology Clinic (Head: Prof. Dr. W. Hartwig) Centre for Postgraduate Medical Education and the Nuclear Medicine Department, Institute of Oncology (Head: Doc. Dr. J. Szymendera) Warsaw
,
H. Siwicki
1   From the Endocrinology Clinic (Head: Prof. Dr. W. Hartwig) Centre for Postgraduate Medical Education and the Nuclear Medicine Department, Institute of Oncology (Head: Doc. Dr. J. Szymendera) Warsaw
› Author Affiliations
Further Information

Publication History

Received:14 September 1976

Publication Date:
10 January 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A new adrenal scanning agent, Adosterol (131I-6β-iodomethyl-19-norcholest-5(10)-en-3β-ol) has been evaluated in three female patients with hypercortic-ism. In one case, characterised by recurrent adrenocortical hyperactivity after bilateral adrenalectomy, a remnant of adrenal tissue was detected. In two other cases, the presence of an adrenal tumour could be excluded. The scan made on the 6th day after the administration of Adosterol was found to be superior in quality to that made on the 13th day.

 

  • References

  • 1 Beierwaltes W. H, Lieberman L. M, Ansari A. N, Nishiyama H. Visualization of human adrenal glands in vivo by scintillation scanning. J. Amer. med. Ass 1971; 216: 275.
    CrossrefGoogle Scholar
  • 2 Conn J. W, Cohen E. L. Versatility of adrenal photo-scanning. Arch. Intern. Med 1973; 131: 554.
    CrossrefPubMedGoogle Scholar
  • 3 Conn J. W, Morita R, Cohen E. L, Beierwaltes W, McDonald J, Herwig K. Primary aldosteronism: photo-scanning of tumours after administration of 131I-19-iodo-cholesterol. Arch. Intern. Med 1972; 129: 417.
    CrossrefPubMedGoogle Scholar
  • 4 Dige-Petersen H, Munker T, Fogh J, Blichert-Toft M, Lund J. O. 131I-19-iodo-cholesterol scintigraphy of the adrenal cortex. Acta Endocr 1975; 80: 81.
    PubMedGoogle Scholar
  • 5 Kasperlik-Zaluska A, Chomicki O. A, Massalski W, Hartwig W, Napiórkowska M. Adrenal scintigraphy with 131I-iodocholesterol in recurrent adrenocortical hyperactivity following bilateral adrenolectomy, (in Polish). Pol. Arch. Med. Wewn 1976; 55: 343.
    PubMedGoogle Scholar
  • 6 Kojima M, Maeda M, Ogawa H, Nitta K, Ito T. New adrenal scanning agent. J. Nucl. Med 1975; 16: 666.
    PubMedGoogle Scholar
  • 7 Müller Chr, Glanzmann Ch, Lütolf U. M, Renk I. W, Horst W. 131Jod-cholesterol (19-C) in der Funktions- und Lokalisationsdiagnostik von Nebennierenrinden-Störungen. Nucl.-Med 1976; 15: 39.
    Google Scholar
  • 8 Schteingart D. E, Conn J. W, Lieberman L. M, Beierwaltes W. H. Persistent or recurrent Cushing’s syndrome after „total“ adrenalectomy. Arch. Intern. Med 1972; 130: 384.
    CrossrefPubMedGoogle Scholar
  • 9 Sasaki T, Ohno A, Tanaka Y, Ohshima M, Matsubara K, Makino N, Mishima A, Yamaguchi H. Adrenal Scintiphotographic Study with 131I-Adosterol, Radioisotopes (Japan). 1976; 25: 94.
    PubMedGoogle Scholar